Indaptus Therapeutics, Inc. (INDP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45339J2042
Indaptus Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -19.83 m USD |
| EBIT | -20.85 m USD |
| Net income | -20.85 m USD |
| Diluted EPS – continuing operations | -21.58 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
More stocks
- Jiusheng Electric Co. LTD (301082.SZ)
- Hanil Cement Co Ltd (003300.KS)
- Editas Medicine, Inc. (EDIT)
- Borussia Dortmund GmbH & Co KGaA (BVB.DE)
- TrueBlue, Inc. (TBI)
- Shandong Xinjufeng Technology Packaging Co. Ltd. A (301296.SZ)
- Investar Holding Corp (ISTR)
- YC Inox Co Ltd (2034.TW)
- Shanxi Yongdong Chemistry Industry Co Ltd (002753.SZ)
- Shinhsiung Natural Gas (8908.TWO)
- Zhejiang Huaye Plastics Machinery Co., Ltd. (301616.SZ)
- Bondex Supply Chain Management Co. Ltd. (603836.SS)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.